Satyanarayana Chava – CEO, Laurus Labs, India
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in India and internationally. It operates through Laurus Generics APIs, Laurus Generics Finished Dosage Forms (FDF), Laurus Synthesis, and Laurus Ingredients divisions.
The Laurus Generics APIs division develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), Hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, oncology, and ophthalmic therapeutic areas. The Laurus Generics Finished Dosage Forms division develops and manufactures oral solid formulations, such as ARVs, anti-diabetic, cardiovascular, and proton pump inhibitors.
The Laurus Synthesis division provides contract development and manufacturing services for pharmaceutical companies. The Laurus Ingredients division manufactures and sells speciality ingredients for use in the nutraceutical/dietary supplements and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. Laurus Labs Limited is a subsidiary of Aptuit LLC.
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for…
Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible…
Contributing to the September 2024 edition of DIA’s Global Forum magazine, Siva Kumar Buddha of Indegene reviews the challenges of risk communication and minimization in India’s healthcare sector. In…
Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent,…
Halewood Laboratories’ Sanchit Chaturvedi discusses the impact of taking on a leadership role in a challenging personal moment; the company’s enduring commitment to innovation and quality; and its planned expansion…
In the words of Founder and Chairman Kaushik Chaturvedi, Halewood Labs’ success since its foundation in the early 1980s can be put down to three key factors: vision and commitment,…
Managing Director Dr Sharvil Patel outlines the objectives behind the rebranding of the Indian pharma company from Zydus Cadila to Zydus Lifesciences, provides insights into the importance of the US…
India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population,…
BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having…
Environmental, Social, and Governance (ESG) concerns have grown in global importance in the last few years due to several factors, including increased awareness of and demand for sustainable investing, the…
Siloed healthcare is no match for a malignant, insidious, and pervasive disease like cancer. Over recent decades, countries and regions across the world have discovered that – in the absence…
See our Cookie Privacy Policy Here
